Institut Català de la Salut
[Campos C, Colomer Castell S, Esteban JI, Quer J] Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Biochemistry and Molecular Biology Department, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Ibañez‐Lligoña M] Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Medicine Department, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain. [Gregori J] Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. [Garcia Cehic D] Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Department of Radiation Oncology, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA. [Andrés C, Piñana M, González Sánchez A] Unitat de Virus Respiratoris, Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBER of Infectious Diseases (CIBERINFEC) Instituto de Salud Carlos III, Madrid, Spain. [Rando Segura A] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Unitat de Virus Respiratoris, Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Microbiologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Esperalba J, Saubí N] Unitat de Virus Respiratoris, Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Microbiologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Cortese MF] Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Microbiologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Tabernero D] Grup de Recerca de les Malalties Hepàtiques, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Hepatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Microbiologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Ferrer R] Servei de Bioquímica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Pumarola T, Antón A] Unitat de Virus Respiratoris, Servei de Microbiologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBER of Infectious Diseases (CIBERINFEC) Instituto de Salud Carlos III, Madrid, Spain. Microbiology Department, Universitat Autònoma de Barcelona (UAB), Bellaterra, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-09-25T07:44:15Z
2025-09-25T07:44:15Z
2025-07
Omicron; Deep‐sequencing; Dual evolution
Òmicron; Seqüenciació profunda; Evolució dual
Ómicron; Secuenciación profunda; Evolución dual
SARS-CoV-2 has evolved from early variants dominating the first (B.1.5, B.1.1) and second (B.1.177) pandemic waves, which exhibited a higher frequency of minority mutants with deletions leading to Defective Viral Genomes (DVGs) in the spike region near the S1/S2 cleavage site than the Alpha, Beta, and Delta variants. The emergence of Omicron has significantly altered the dominant variant profile, with Omicron subvariants now representing 100% of circulating viruses. To monitor the evolution and adaptation of Omicron in the human population, a deep-sequencing study was performed in RNA samples of BA.1, BA.1.1, BA.2, BA.5, BQ.1.1, XBB.1.5 and BA.2.86 Omicron subvariants. The findings reveal two occurrences of similar evolutionary patterns within SARS-CoV-2 characterized by a shift from a significant to a very low production of DVGs. This event suggests that DVGs might play a role in the virus's spread and adaptation for persistence in infected humans.
This study was supported by the Centro para el Desarrollo Tecnológico Industrial (CDTI) of the Spanish Ministry of Economy and Business, grant number IDI-20200297; Grant PID2021-126447OB-I00 funded by MCIN/AEI/10.13039/501100011033 and by the ERDF A way of making Europe; Fondo de Investigación Sanitaria, Spanish Ministry of Economy and Competitiveness (grants FIS PI19/00301, PI19/00533, PI22/00258, PI22/00023, and PI23/01065); CIBER—Consorcio Centro de Investigación Biomédica en Red—(CIBERINFEC, ISCIII—CIBER of Infectious Diseases & CIBEREHD, ISCIII—CIBER of Hepatic and Digestive Diseases), Instituto de Salud Carlos III, Ministry of Science and Innovation and the European Union—NextGenerationEU. Research contributions of Wageningen Bioveterinary Research are funded from the ERRAZE (Early Response and Rapid Action Zoonotic Emergencies Program). C.C. received a predoctoral fellowship from the Vall d'Hebron Institute of Research (VHIR). M.I.-L. was supported by a fellowship from the “La Caixa” Foundation (ID 100010434), with code “LCF/BQ/DR23/12000020”. S.C-C. received support from the Spanish Ministry of Education grant FPU21/04150.
Article
Published version
English
COVID-19 (Malaltia); Anomalies cromosòmiques; Genomes; Seqüència de nucleòtids; DISEASES::Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections; PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation; PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Structures::Genome::Genome, Microbial::Genome, Viral; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Genetic Techniques::Sequence Analysis::High-Throughput Nucleotide Sequencing; ENFERMEDADES::virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus; FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación; FENÓMENOS Y PROCESOS::fenómenos genéticos::estructuras genéticas::genoma::genoma microbiano::genoma viral; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::técnicas genéticas::análisis de secuencias::secuenciación de nucleótidos de alto rendimiento
Wiley
Journal of Medical Virology;97(7)
https://doi.org/10.1002/jmv.70476
info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PID2021-126447OB-I00
info:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F00301
info:eu-repo/grantAgreement/ES/PE2017-2020/PI19%2F00533
info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI22%2F00258
info:eu-repo/grantAgreement/ES/PEICTI2021-2023/PI22%2F00023
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - VHIR [1665]